113 related articles for article (PubMed ID: 36959108)
1. Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with
Zhou D; Zuo Y; Pan Z
J Med Chem; 2023 Apr; 66(7):4979-4998. PubMed ID: 36959108
[TBL] [Abstract][Full Text] [Related]
2. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.
Guo W; Liu R; Ono Y; Ma AH; Martinez A; Sanchez E; Wang Y; Huang W; Mazloom A; Li J; Ning J; Maverakis E; Lam KS; Kung HJ
Mol Pharmacol; 2012 Nov; 82(5):938-47. PubMed ID: 22899868
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
Tang G; Liu L; Wang X; Pan Z
Eur J Med Chem; 2019 Jul; 173():167-183. PubMed ID: 30999237
[TBL] [Abstract][Full Text] [Related]
4. Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70.
Hussain A; Mohammad DK; Gustafsson MO; Uslu M; Hamasy A; Nore BF; Mohamed AJ; Smith CI
J Biol Chem; 2013 Mar; 288(10):7338-50. PubMed ID: 23293025
[TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Zhong Y; Dong S; Strattan E; Ren L; Butchar JP; Thornton K; Mishra A; Porcu P; Bradshaw JM; Bisconte A; Owens TD; Verner E; Brameld KA; Funk JO; Hill RJ; Johnson AJ; Dubovsky JA
J Biol Chem; 2015 Mar; 290(10):5960-78. PubMed ID: 25593320
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Wang X; Xue G; Pan Z
Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
[TBL] [Abstract][Full Text] [Related]
7. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of IL-2 inducible T-cell kinase alleviates T-cell activation and murine myocardial inflammation associated with CVB3 infection.
He F; Yao H; Xiao Z; Han J; Zou J; Liu Z
Mol Immunol; 2014 May; 59(1):30-8. PubMed ID: 24462896
[TBL] [Abstract][Full Text] [Related]
9. Itk, a T cell-specific tyrosine kinase, is required for CD2-mediated interleukin-2 promoter activation in the human T cell line Jurkat.
Tanaka N; Abe H; Yagita H; Okumura K; Nakamura M; Sugamura K
Eur J Immunol; 1997 Apr; 27(4):834-41. PubMed ID: 9130632
[TBL] [Abstract][Full Text] [Related]
10. ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas.
Jiang B; Weinstock DM; Donovan KA; Sun HW; Wolfe A; Amaka S; Donaldson NL; Wu G; Jiang Y; Wilcox RA; Fischer ES; Gray NS; Wu W
Cell Chem Biol; 2023 Apr; 30(4):383-393.e6. PubMed ID: 37015223
[TBL] [Abstract][Full Text] [Related]
11. A role for the Tec family kinase ITK in regulating SEB-induced interleukin-2 production in vivo via c-jun phosphorylation.
Ragin MJ; Hu J; Henderson AJ; August A
BMC Immunol; 2005 Jul; 6():19. PubMed ID: 16042784
[TBL] [Abstract][Full Text] [Related]
12. IL-2 Inducible Kinase ITK is Critical for HIV-1 Infection of Jurkat T-cells.
Hain A; Krämer M; Linka RM; Nakhaei-Rad S; Ahmadian MR; Häussinger D; Borkhardt A; Münk C
Sci Rep; 2018 Feb; 8(1):3217. PubMed ID: 29453458
[TBL] [Abstract][Full Text] [Related]
13. Selective Itk inhibitors block T-cell activation and murine lung inflammation.
Lin TA; McIntyre KW; Das J; Liu C; O'Day KD; Penhallow B; Hung CY; Whitney GS; Shuster DJ; Yang X; Townsend R; Postelnek J; Spergel SH; Lin J; Moquin RV; Furch JA; Kamath AV; Zhang H; Marathe PH; Perez-Villar JJ; Doweyko A; Killar L; Dodd JH; Barrish JC; Wityak J; Kanner SB
Biochemistry; 2004 Aug; 43(34):11056-62. PubMed ID: 15323564
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
16. Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.
Lechner KS; Neurath MF; Weigmann B
J Mol Med (Berl); 2020 Oct; 98(10):1385-1395. PubMed ID: 32808093
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-155 acts as an anti-inflammatory factor in orbital fibroblasts from Graves' orbitopathy by repressing interleukin-2-inducible T-cell kinase.
Choi YJ; Kim C; Choi EW; Lee SH; Chae MK; Jun HO; Kim BY; Yoon JS; Jang SY
PLoS One; 2022; 17(8):e0270416. PubMed ID: 35980936
[TBL] [Abstract][Full Text] [Related]
18. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.
Yu X; Xu J; Xie L; Wang L; Shen Y; Cahuzac KM; Chen X; Liu J; Parsons RE; Jin J
J Med Chem; 2021 Dec; 64(24):18054-18081. PubMed ID: 34855399
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Dubovsky JA; Beckwith KA; Natarajan G; Woyach JA; Jaglowski S; Zhong Y; Hessler JD; Liu TM; Chang BY; Larkin KM; Stefanovski MR; Chappell DL; Frissora FW; Smith LL; Smucker KA; Flynn JM; Jones JA; Andritsos LA; Maddocks K; Lehman AM; Furman R; Sharman J; Mishra A; Caligiuri MA; Satoskar AR; Buggy JJ; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2013 Oct; 122(15):2539-49. PubMed ID: 23886836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
